Haemonetics (NYSE:HAE) Given New $62.00 Price Target at JPMorgan Chase & Co.

Haemonetics (NYSE:HAE) had its target price lowered by JPMorgan Chase & Co. from $74.00 to $62.00 in a report released on Friday morning,Benzinga reports. The firm currently has a neutral rating on the medical instruments supplier’s stock.

A number of other analysts have also weighed in on HAE. Robert W. Baird set a $67.00 target price on Haemonetics in a research note on Friday. BTIG Research restated a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research note on Friday, February 6th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Barrington Research set a $94.00 target price on Haemonetics in a research note on Friday, February 6th. Finally, Mizuho lowered their target price on Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $79.89.

Haemonetics Stock Performance

Haemonetics stock opened at $55.06 on Friday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.15. The stock has a fifty day moving average price of $59.53 and a two-hundred day moving average price of $66.68. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32. The firm has a market capitalization of $2.56 billion, a P/E ratio of 27.26, a P/E/G ratio of 1.06 and a beta of 0.53.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. During the same period in the prior year, the company posted $1.24 earnings per share. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts anticipate that Haemonetics will post 5.28 EPS for the current fiscal year.

Institutional Trading of Haemonetics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. bought a new position in Haemonetics in the fourth quarter valued at about $26,000. True Wealth Design LLC boosted its holdings in Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 335 shares during the last quarter. Leonteq Securities AG bought a new position in Haemonetics in the fourth quarter valued at about $30,000. EverSource Wealth Advisors LLC boosted its holdings in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new position in Haemonetics in the fourth quarter valued at about $34,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics News Summary

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q4 results that topped expectations, with EPS of $1.29 vs. $1.28 expected and revenue of $346.35 million vs. $336.83 million expected, while revenue rose 4.8% year over year. Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026
• Positive Sentiment: The company also guided FY 2027 EPS to $5.258-$5.307 and reiterated revenue around $1.4 billion, signaling continued growth from Persona PLUS rollout and a rebound in IVT volumes. Haemonetics projects FY 2027 revenue growth of 4% to 7% as Persona PLUS rollout and IVT rebound efforts continue
• Neutral Sentiment: JPMorgan lowered its price target on Haemonetics to $62 from $74 and kept a Neutral rating, reflecting more cautious expectations even though the new target still sits above the recent share price. Read More
• Neutral Sentiment: Several earnings call transcripts and summaries were published, but they mainly reinforce the same themes of modest earnings beats and management’s forward guidance. Haemonetics (HAE) Q4 2026 Earnings Transcript

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.